Drug Discovery Informatics Market Size, Share, Workflow (Discovery Informatics and Biocontent Management), Services (Sequencing & Target Data Analysis, Library & Database Sequencing, Clinical Trial Data Management, Docking, Molecular Modeling, and Others), End-Users (Biotechnology & Pharmaceutical Companies, Contract Research Organization, and Others), and Region - Trends, Analysis, and Forecast till 2035

• By 2035, the target market is expected to increase at a rate of USD 10.4 Billion.
• Drug discovery informatics market size was valued at USD 3.8 Billion in 2024.
• The market is expanding at a CAGR of 10.8%.

Drug discovery informatics is the application of computational tools, techniques, and data analysis to the drug discovery process. It involves technology and data to accelerate the identification of new drug candidates, optimize drug designs, and improve the efficiency of the drug development.

The increasing focus on using computation tools, artificial intelligence (AI), machine learning, and data analysis for the drug discovery process, is expected to drive target market growth. Rising demand for personalized medicine, increasing use of bio data, growing investment in research & development, resulting to drive drug discovery informatics market growth over the forecast period.

Impact of AI on Drug Discovery Informatics:

Artificial Intelligence (AI) significantly transforming drugs by interpreting AI technologies, especially machine learning and deep learning. AI algorithms can analyze vast amount of biological data to identify potential drug targets, by reducing the time as compared to traditional methods. AI can generate novel drug candidates by designing new molecules, and help researchers to predict biological systems and enhance the development of personalized therapeutics and improves the precision of drug intervention.

Key Drivers of Target Market:

Growing Research and Development Investment is Expected to Pitch Market Growth

The biotechnology and pharmaceutical companies are increasing their investments in research and development (R&D), to accelerate the need for more advanced technologies, such as drug discovery informatics. The growing investment aim to enhance the efficiency and effectiveness of the drug discovery process for adopting informatics tools for better precise decisions. Diseases, such as cancer, neurological disorders, and rare genetic diseases require advanced, targeted approaches. As the, pharmaceutical companies are forming partnerships with AI, data analytics, and biotech companies, to integrate cutting-edge drug discovery informatics platform, resulting to drive drug discovery informatics market growth.

• For instance, in May 2024, Accenture invested in Turbine to accelerate potential for drug development workstreams. Turbine’s core technology, known as the Simulated Cell platform, utilizes machine learning to understand human cells mechanisms. This platform is aimed to support technology and digital capabilities that drive innovation in AI-based drug discovery by providing more effective treatment and enhancing patient care.

Restraints:

Data Privacy and Security Concerns Can Limit Market Expansion

Drug informatics contain large volume of sensitive data being used in AI-driven drug development process. Drug discovery informatics contains large datasets, including patient data, genetic information, clinical trial results, and proprietary drug information, thus the risk of data breaches is high. Hackers could target databases containing this sensitive information, leading to unauthorized access and potential misuse.

• Counterbalance Statements: Advanced encryption techniques, multi-factor authentication, and secure cloud platforms are increasingly adopted to safeguard sensitive data. Regulatory standards such as, GDPR (General Data Protection Regulation) and HIPAA (Health Insurance Portability and Accountability Act) are setting clear guidelines for data protection, convincing organizations to adopt stronger data security measures.

Opportunities & Market Trends:

Integration of AI in Drug Discovery Informatics Expected to Boost Market Growth

The integration of AI in drug discovery informatics represent significant opportunity for the market, by delivering more effective and efficient solutions for the pharmaceutical and biotechnology industries. AI algorithms generate novel-drug components and predicts their interaction with biological targets, by improving their potency, bioavailability, and safety profile. AI algorithms can analyze complex patterns and relationships within biological system, to identify novel drug targets, which can be difficult using traditional methods, resulting to drive drug discovery informatics market growth.

• For instance, in February 2023, Insilico Medicine approved by FDA’s first Orphan Drug Designation for a drug discovered and designed using artificial intelligence (AI). INS018_055 was Insilico’s first owned program in which AI was used to identify a novel target, which the company has identified only as Target X. Target X generate novel small molecules through the company’s pharma using AI platform. Integration of AI aimed to useful for the finding new drug targets and effective drug candidates.

The drug discovery informatics market is classified into workflow, Services, end-user, and region.

Workflow:

Discovery informatics and biocontent management are the workflow segment for drug discovery informatics market. The discovery informatics segments are dominating segment in target market, due to it is focus on developing precision medicine. Precision medicine provides personalized medical care tailored to an individual’s genetic and molecular profiles. The governments are encouraging to the adoption of bioinformatics tools for the drug discovery processes. The rising prevalence for personalized medical care, and growing importance of drug discovery, is anticipated to the growth of the drug discovery informatics market share.

• For instance, in September 2020, the Indian government launched a Drug Discovery Hackathon (DDH2020) platform as the open source of drug discovery Hackathon against COVID-19. This initiative is aimed to promote the identification, validation, and design of an effective molecule against the COVID-19 virus using drug discovery informatics tools.

Services:

The target market, by services, is segmented into sequencing & target data analysis cell line, library & database sequencing, clinical trial data management docking, molecular modeling, and others. The sequencing & target data analysis holds the largest drug discovery informatics market share due to rising adoption of bioinformatic solutions. Bioinformatic solutions are widely applicable in primary and secondary databases of nucleic acids, proteins, and other biomolecule sequences. Drug discovery informatics enables identify gene and targeted proteins, for the development of potential drugs, is responsible to drive drug discovery informatics market growth.

• For instance, in December 2024, Quantum-Si Incorporated, the protein sequencing company, introduced Platinum Library Prep. Kit, known as V2. An advanced tool for single-molecule protein sequencing, which was designed for simplify workflows and expand researchers ability to analyze specific drug.

End-User:

Biotechnology & pharmaceutical companies, contract research organization, others are classified by end-user in focused market. The biotechnology & pharmaceutical companies dominate the market. Pharmaceutical companies are investing in research and development (R&D) to discover new drugs, and advanced informatics solutions for tasks, such as drug design, target identification, preclinical testing, and clinical trial management. The large amounts of clinical genomics, and chemical data can be analyzed and processed using drug discovery informatics platforms, resulting to the growth of drug discovery informatics market globally.

Region:

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: North America holds the largest share with 37.3% of target market due to the increasing investments in research & development activities and presence of major key players in this region that focuses on drug discovery and advancements in data mining & analytics technologies. The more efficient and effective analysis of large volumes of data in drug discovery process, leading to growth of drug discovery informatics market expansion.

• For instance, in December 2020, Atomwise, announced partnership with FutuRx, for the introduction of Atomwise’s AtomNet platform for AI-based drug discovery. This collaboration aimed to provide small-molecule drug discovery, and early stage therapeutic technologies by the launching of A2i therapeutics company.

Asia Pacific: Asia pacific is expected to experience the fastest-growth in the region during the forecast period. The rapid growth in pharmaceutical & biotechnology industries and the expanding number of contract research organizations, leading to growth of target market size. The advancement in data analytics technologies, and growing investment in R&D by governments, is anticipated to drive drug discovery informatics market growth in upcoming years.

Drug Discovery Informatics Market Report Scope:

Segmentation:

By Workflow:

• Discovery Informatics
• Biocontent Management

By Services:

• Sequencing & Target Data Analysis
• Library & Database Sequencing
• Clinical Trial Data Management
• Docking
• Molecular Modeling
• Others

By End-User:

• Biotechnology & Pharmaceutical Companies
• Contract Research Organization
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the drug discovery informatics market includes Boehringer Ingelheim International GmbH, Inc, Bio-Techne, Collaborative Drug Discovery Inc., IBM, and others. Various companies are focusing on new product launches, product approvals, and partnerships and collaborations to maintain their dominance in the market.

List of Key Players in the Market:

• Boehringer Ingelheim International GmbH
• Collaborative Drug Discovery Inc.
• IBM
• Selvita
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Eurofins DiscoverX
• Exscientia
• Insilico Medicine
• PerkinElmer Inc.
• Schrödinger, Inc.
• Certara, USA.
• Infosys Limited
• BenevolentAI
• Chemaxon Ltd.

• In May 2024, Certara, Inc., announced collaboration with China’s Cloud scientific, aimed to discover informatics platform, D360, and Certara’s secure and flexible GPT AI. The D360 scientific informatics platform used for advanced research for small molecule and biological drugs, and GPTs AI used across drug development from early discovery to clinical trials. This partnership aimed to provide biopharmaceutical companies with advanced tools and solutions in drug development.
• In February 2024, Eurofins launched DiscoveryAI SAFIRE a new AI-driven platform for drug discovery. SAFIRE is an advanced platform that contains proprietary datasets, artificial intelligence (AI), and machine learning (ML), offering a unique capability for expediting discovery. SAFIRE provides essential features, such as scoring functionality to help in decision-making and a comprehensive collection of predictive ADMET (Absorption, Distribution, Metabolism, excretion, and Toxicity) properties of molecules.

Analyst View:

The drug discovery informatics market is significantly focusing on increase adoption of AI and machine learning and personalized medicine, leading to the target market growth. The rising investment in R&D, and increasing demand for AI-based tools, analytics platforms, and cloud-based solutions in drug discovery, is anticipated to growth of drug discovery informatics market expansion.

More Related Reports

Drug Discovery Informatics Market
AI-Enabled Drug Discovery and Clinical Trials Market
Cloud Database Market
Enterprise Database Systems Market
Enterprise Database Management System (DBMS) Market